
Dermatologist

No OPD information available
Plaque Psoriasis
Psoriasis
Atopic Dermatitis
Actinic Keratosis
Hidradenitis Suppurativa
Seborrheic Keratosis
Acne
Autosomal Recessive Hypotrichosis
Basal Cell Skin Cancer
Boils
Dermatitis Herpetiformis
Gastrointestinal Perforation
Granuloma Annulare
Muir-Torre Syndrome
Necrosis
Pellagra
Psoriatic Arthritis
Punctate Porokeratosis
Squamous Cell Skin Carcinoma
Telangiectasia
Varicose Veins
Lynda J. Spelman is a female healthcare provider who helps people with various skin conditions like plaque psoriasis, acne, and skin cancer. She also treats other conditions such as gastrointestinal perforation and varicose veins.
Lynda J. Spelman uses special skills and treatments to care for her patients. She communicates with patients in a friendly and clear way, which helps them trust her. Patients feel comfortable discussing their health concerns with her.
To stay updated with the latest medical knowledge, Lynda J. Spelman reads research articles and attends conferences. This helps her provide the best care for her patients. She also collaborates with other medical professionals to share knowledge and improve patient outcomes.
Lynda J. Spelman's work has positively impacted many patients' lives. For example, her research on rocatinlimab for atopic dermatitis has led to better treatment options for patients. She is also involved in clinical trials to study new treatments for conditions like atopic dermatitis in pediatric patients.
One of Lynda J. Spelman's notable publications is the study on rocatinlimab in atopic dermatitis, which was published in Immunotherapy. She is also actively involved in a Phase 3 clinical trial evaluating the safety and efficacy of baricitinib in pediatric patients with atopic dermatitis.
Overall, Lynda J. Spelman is a dedicated healthcare provider who uses her expertise and research to help patients with skin conditions. Her commitment to staying updated with the latest medical knowledge and collaborating with colleagues shows her dedication to providing the best care possible.
Enrollment Status: Active not recruiting
Published: March 03, 2025
Intervention Type: Drug
Study Drug:
Study Phase: Phase 3
